Theravance Biopharma Inc (TBPH)
9.02
-0.15
(-1.64%)
USD |
NASDAQ |
Apr 25, 10:32
Theravance Biopharma Gross Profit Margin (Quarterly)
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2018 | 95.98% |
| September 30, 2018 | 94.51% |
| June 30, 2018 | |
| March 31, 2018 | 90.07% |
| December 31, 2017 | 30.99% |
| September 30, 2017 | 76.96% |
| June 30, 2017 | 61.13% |
| March 31, 2017 | 81.70% |
| December 31, 2016 | 79.87% |
| September 30, 2016 | 98.26% |
| Date | Value |
|---|---|
| June 30, 2016 | 88.34% |
| March 31, 2016 | 95.77% |
| December 31, 2015 | 17.78% |
| September 30, 2015 | 94.57% |
| June 30, 2015 | 92.92% |
| March 31, 2015 | 98.18% |
| December 31, 2014 | -124.8% |
| September 30, 2014 | 94.18% |
| June 30, 2014 | 90.62% |
| March 31, 2014 | 80.11% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Corcept Therapeutics Inc | 98.61% |
| Nektar Therapeutics | 69.51% |
| Vanda Pharmaceuticals Inc | 92.36% |
| Fate Therapeutics Inc | -- |
| FibroGen Inc | 80.08% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -17.79% |
| Return on Assets | -11.56% |
| Return on Invested Capital | -17.79% |
| Profit Margin (Quarterly) | -48.45% |
| Operating Margin (Quarterly) | -37.56% |
| Return on Net Operating Assets | -83.47% |